NICE has estimated that around 40% of people with COPD have elevated blood levels of eosinophils and, if half the eligible ...

Dupilumab, a simple pre-filled pen that people inject themselves with every two weeks, is the first biologic that targets both the symptoms of COPD and an underlying cause of the disease. It brings ...

A biologic injection that reduces chronic obstructive pulmonary disease (COPD) flare-ups by around a third has been approved for use on the NHS in England and Wales. The National Institute for Health ...

The National Institute for Health and Care Excellence (NICE), has published final draft guidance recommending dupilumab as a ...

NICE has approved the first targeted treatment for chronic obstructive pulmonary disease (COPD), offering a new option to up ...

NICE has recommended dupilumab for adults with uncontrolled COPD and raised eosinophils, citing fewer exacerbations and ...

Sanofi and Regeneron’s Dupixent (dupilumab) has received positive final draft guidance from the National Institute for Health ...

Early identification and treatment of patients with COPD at risk of exacerbation are crucial for better outcomes. Single-inhaler triple therapy (SITT) users showed improved exacerbation rates and ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the world’s first low-carbon version of a triple-combination inhaler for chronic obstructive pulmonary disease (COPD). The ...

UK pharma major GSK’s Nucala (mepolizumab) has recently received approval in China as add-on maintenance treatment for adults ...